ArticlebioRxiv : the preprint server for biology2025
Frequency-Aware Interpretable Deep Learning Framework for Alzheimer's Disease Classification Using rs-fMRI.
Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Gaining insight into the spectral and temporal alterations in brain connectivity associated with Alzheimer's disease (AD) may offer pathways toward more informative biomarkers and a deeper understanding of disease mechanisms. We propose FINE (Frequency-aware Interpretable Neural Encoder), a novel deep learning model designed to capture multi-scale temporal and frequency-specific patterns in dynamic functional network connectivity (dFNC) derived from resting-state fMRI. FINE integrates multiple expert branches, including convolutional layers, learnable wavelet layers, transformers, and static encoders, enabling the joint modeling of temporal evolution and spectral content of brain networks in an end-to-end framework. Beyond classification, FINE supports frequency-wise interpretability by aligning gradient-based saliency maps with statistical group differences, revealing potential robust, biologically meaningful biomarkers of AD. Evaluated on the large OASIS-3 dataset (856 subjects), FINE achieves AD classification performance (ROC-AUC 0.769) and provides insights into frequency-specific connectivity disruptions, particularly within subcortical, sensorimotor, and cerebellar networks. Our results demonstrate that incorporating frequency-aware modeling and interpretable architectures can advance both disease classification and underlying functional disruption of AD-related brain dynamics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.